Jacky Vonderscher, Enyo Pharma CEO
Scoop: After hep B setback, an OrbiMed-backed NASH biotech hunts for partners as it raises Series C
Almost four and a half years after uncloaking a €40 million Series B, a small French biotech hopes to secure another round of financing to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
